Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06530082 | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | not yet recruiting | Phase 1 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER |
| 1 |
| Mar 29, 2024 |
| clinicaltrials |
| NCT06140576 | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | not yet recruiting | Phase 1 / Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2024source: clinicaltrials